Companies › Rapport Therapeutics
1 active drug program in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Neurology, Psychiatry; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RAP-219 GABA-A positive allosteric modulator | GABRA | Phase 3 | Focal Seizure; Bipolar 1 Disorder; Focal Epilepsy; Epilepsy | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07046494 | RAP-219 | Phase 2 | Bipolar 1 Disorder | Psychiatry | Aug 2026 |
| NCT07923097 | RAP-219 | Phase 1 | Epilepsy | Neurology | Jun 2027 |
| NCT07219407 | RAP-219 | Phase 2 | Focal Epilepsy | Neurology | Feb 2028 |
| NCT07594119 | RAP-219 | Phase 3 | Focal Seizure | Neurology | Jul 2029 |
| NCT07563881 | RAP-219 | Phase 3 | Focal Seizure | Neurology | Jul 2029 |
Cash and short-term investments of $395m on 2026-09-30; operating cash outflow about $129m a year; runway about 37 months at that burn, to Oct 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Lipocine Xenon Pharmaceuticals Sichuan Jishengtang Pharmaceutical Impax Laboratories Intra-Cellular Therapies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.